Cargando…

Atogepant for the prevention of episodic migraine in adults

OBJECTIVE: Atogepant is a newly approved medication for the prevention of migraine. This review aims to discuss the efficacy, safety, cost, and place in therapy of atogepant. METHODS: The authors performed a systematic search for sources, including articles, abstracts, and poster presentations. Quer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Switzer, Maranda Paige, Robinson, Joseph Edward, Joyner, Kayla Rena, Morgan, Kelsey Woods
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549103/ https://www.ncbi.nlm.nih.gov/pubmed/36226229 http://dx.doi.org/10.1177/20503121221128688

Ejemplares similares

Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations
por: Cohen, Fred, et al.
Publicado: (2022)

Eptinezumab: A calcitonin gene-related peptide monoclonal antibody infusion for migraine prevention
por: Morgan, Kelsey Woods, et al.
Publicado: (2021)

Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety
por: Lattanzi, Simona, et al.
Publicado: (2022)

Novel Oral CGRP Receptor Antagonist Atogepant in the Prevention of Migraine
por: Chowdhury, Selia, et al.
Publicado: (2023)

Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial
por: Schwedt, Todd J, et al.
Publicado: (2021)

The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials
por: Tao, Xinyu, et al.
Publicado: (2022)

Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial
por: Lipton, Richard B., et al.
Publicado: (2022)

Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial
por: Lipton, Richard B., et al.
Publicado: (2023)

Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults
por: Min, K. Chris, et al.
Publicado: (2020)

Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial
por: Ashina, Messoud, et al.
Publicado: (2023)

The acute and preventative treatment of episodic migraine
por: Miller, Sarah
Publicado: (2012)

Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021)

Episodic Migraine and Older Adults
por: Riggins, Nina, et al.
Publicado: (2022)

Pediatric migraine and episodic syndromes that may be associated with migraine
por: Spiri, Daniele, et al.
Publicado: (2014)

Single‐Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021)

Efficacy and Tolerability of Erenumab for Prevention of Episodic Migraine in India
por: Chowdhury, Debashish, et al.
Publicado: (2022)

A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults
por: Sakai, Fumihiko, et al.
Publicado: (2019)

Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine
por: Root, Shane, et al.
Publicado: (2023)

Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants
por: Ankrom, Wendy, et al.
Publicado: (2020)

Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons
por: Melo-Carrillo, Agustin, et al.
Publicado: (2020)

Vestibular migraine: the most frequent entity of episodic vertigo
por: Dieterich, Marianne, et al.
Publicado: (2016)

Pediatric Episodic Migraine with Aura: A Unique Entity?
por: Shapiro, Hannah F.J., et al.
Publicado: (2021)

Defining the Differences Between Episodic Migraine and Chronic Migraine
por: Katsarava, Zaza, et al.
Publicado: (2011)

Interventional Procedures in Episodic Migraine
por: Plato, Brian M., et al.
Publicado: (2020)

Effect of preventive treatment on health–related quality of life in episodic migraine
por: Bordini, C. A., et al.
Publicado: (2005)

Sex and Gender Considerations in Episodic Migraine
por: Ahmad, Sarah R., et al.
Publicado: (2022)

Migraine with benign episodic unilateral mydriasis
por: Skeik, Nedaa, et al.
Publicado: (2011)

Response Predictors of Repetitive Neuromuscular Magnetic Stimulation in the Preventive Treatment of Episodic Migraine
por: Börner, Corinna, et al.
Publicado: (2022)

Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies
por: Detke, Holland C., et al.
Publicado: (2019)

A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single‐Dose, Phase 1 Crossover Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021)

Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis
por: Kitamura, Shigekazu, et al.
Publicado: (2023)

Pharmacologic prevention of migraine
por: Tzankova, Velina, et al.
Publicado: (2023)

Alterations in pain processing circuitries in episodic migraine
por: Mungoven, Tiffani J., et al.
Publicado: (2022)

The borderland of migraine with aura: episodic unilateral mydriasis
por: Maggioni, F., et al.
Publicado: (2010)

Cerebral neurocysticercosis mimicking or comorbid with episodic migraine?
por: Fogang, Yannick Fogoum, et al.
Publicado: (2014)

Depression and risk of transformation of episodic to chronic migraine
por: Ashina, Sait, et al.
Publicado: (2012)

Early onset of efficacy with erenumab in patients with episodic and chronic migraine
por: Schwedt, Todd, et al.
Publicado: (2018)

Optimal Dose of Erenumab for Preventive Treatment of Episodic Migraine: A Systematic Review and Meta-Analysis
por: Yang, Yanbo, et al.
Publicado: (2022)

Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis
por: Goadsby, Peter J, et al.
Publicado: (2019)

Fremanezumab for Episodic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials
por: Saigoh, Kazumasa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6fh4vs7sovrn0et7cleo6ohigq